Year : 2022 | Volume
: 30 | Issue : 4 | Page : 257--260
Prenatal diagnosis of euploid increased nuchal translucency on fetal ultrasound (I): Noonan syndrome: Prenatal diagnosis and genetic testing
Department of Obstetrics and Gynecology; Department of Medical Research, MacKay Memorial Hospital, Taipei; School of Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung; Institute of Clinical and Community Health Nursing; Department of Obstetrics and Gynecology, School of Medicine, National Yang Ming Chiao Tung University, Taipei; Department of Medical Laboratory Science and Biotechnology, College of Medical and Health Science, Asia University, Taichung, Taiwan
Prof. Chih-Ping Chen
Department of Obstetrics and Gynecology, MacKay Memorial Hospital, No. 92, Section 2, Chung-Shan North Road, Taipei 10449
Prenatal diagnosis of euploid increased nuchal translucency (NT) remains a challenge to obstetricians and genetic counselors although increased euploid NT at prenatal diagnosis can be associated with a favorable outcome. Prenatal diagnosis of euploid increased NT should include a differential diagnosis of pathogenetic copy number variants and RASopathy disorders (RDs) including Noonan syndrome (NS). Therefore, chromosomal microarray analysis, whole-exome sequencing, RD testing, and protein-tyrosine phosphatase, nonreceptor type 11 (PTPN11) gene testing may be necessary under such a circumstance. In this report, a comprehensive review of NS with its prenatal diagnosis and genetic testing is presented.
|How to cite this article:|
Chen CP. Prenatal diagnosis of euploid increased nuchal translucency on fetal ultrasound (I): Noonan syndrome: Prenatal diagnosis and genetic testing.J Med Ultrasound 2022;30:257-260
|How to cite this URL:|
Chen CP. Prenatal diagnosis of euploid increased nuchal translucency on fetal ultrasound (I): Noonan syndrome: Prenatal diagnosis and genetic testing. J Med Ultrasound [serial online] 2022 [cited 2023 Feb 5 ];30:257-260
Available from: http://www.jmuonline.org/text.asp?2022/30/4/257/360633
Prenatal diagnosis of euploid increased nuchal translucency (NT) remains a challenge to obstetricians and genetic counselors although euploid increased NT at prenatal diagnosis can be associated with a favorable outcome. Prenatal diagnosis of euploid increased NT should include a differential diagnosis of pathogenetic copy number variants and RASopathy disorders (RDs) including Noonan syndrome (NS). Therefore, chromosomal microarray analysis (CMA), whole-exome sequencing (WES), RD testing, and protein-tyrosine phosphatase, nonreceptor type 11 (PTPN11) gene testing may be necessary under such a circumstance.
Noonan Syndrome and Genetic Heterogeneity
NS1 (OMIM 163950) is an autosomal dominant disorder caused by heterozygous mutation in the PTPN11 gene (OMIM 176876) and is characterized by short stature, congenital heart defects such as pulmonic stenosis and hypertrophic cardiomyopathy, facial dysmorphism of a broad forehead, hypertelorism, downslanting palpebral fissures, a high-arched palate and low-set ears, and other abnormalities including skeletal defects of chest and spine, webbed neck, mental retardation, and cryptorchidism.,,,,, NS1 caused by PTPN11 gene accounts for about half of the patients with NS.
PTPN11 (OMIM 176876) located 12q24.13 encodes protein-tyrosine phosphatase, nonreceptor type 11 or SHP-2. Mutations of PTPN11 have been reported to be associated with juvenile myelomonocytic leukemia and autosomal dominant LEOPARD syndrome 1 (OMIM 151100), metachondromatosis (OMIM 156250), and NS1 (OMIM 163950). Tartaglia et al. identified mutations in the PTPN11 gene in more than 50% of the patients with NS. They found that gain-of-function changes by PTPN11 mutations result in excessive SHP-2 activity and cause the pathogenesis of NS. NS has genetic heterogeneity. In addition to the common type of NS1 caused by PTPN11 gene mutation, other autosomal dominant NS types include NS3 (OMIM 609942) caused by KRAS (OMIM 190070) mutations, NS4 (OMIM 610733) caused by SOS1 (OMIM 182530) mutations, NS5 (OMIM 611553) caused by RAF1 (OMIM 164760) mutations, NS6 (OMIM 613224) caused by NRAS (OMIM 164790) mutations, NS7 (613706) caused by BRAF (OMIM 164757) mutations, NS8 (OMIM 615355) caused by RIT1 (OMIM 609591) mutations, NS9 (OMIM 616559) caused by SOS2 (OMIM 601247) mutations, NS10 (616564) caused by LZTR1 (OMIM 600574) mutations, NS11 (OMIM 618499) caused by MRAS (OMIM 608435) mutations, NS12 (OMIM 618624) caused by RRAS2 (OMIM 600098) mutations, and NS13 (OMIM 619087) caused by MAPK1 (OMIM 176948) mutations. Autosomal recessive forms of NS include NS2 (OMIM 605275) caused by LZTR1 (OMIM 600574) mutations and NS14 (OMIM 619745) caused by SPRED2 (OMIM 609292) mutations. Other autosomal dominant NS-like disorders include NSLH1 (NS-like disorders with loose anagen hair-1) (OMIM 607721) caused by SHOC2 (OMIM 602775) mutations, NSLH2 (NS-like disorder with loose anagen hair-2) (OMIM 617506) caused by PPP1CB (OMIM 600590) mutations, NSLL (NS-like disorder with or without juvenile myelomonocytic leukemia) (OMIM 613563) caused by CBL (OMIM 165360) mutations, and NFNS (neurofibromatosis-NS) (OMIM 601321) caused by NF1 (OMIM 162200) mutations.
Noonan Syndrome: Prenatal Diagnosis and Genetic Testing
Prenatal diagnosis of increased NT and/or cystic hygroma associated with chromosomal abnormalities and other genetic disorders such as NS has been well described. As early as in 1982, Cowchock et al. found that not all cystic hygromas at prenatal diagnosis occur in Turner syndrome and suggested that cystic hygromas can be a part of a variety of genetic malformation syndromes. In 1992, Nicolaides et al. found that the incidence of chromosomal abnormalities (mainly trisomy 21, trisomy 13, trisomy 18, and Turner syndrome) was 35% in fetuses with NT of 3–8 mm, compared with only 1% in fetuses with NT <3 mm. In 1995, Pandya et al. reported screening for fetal trisomies by maternal age and fetal NT thickness at 10–14 weeks of gestation and found that NT > 95th centile occurred in 77% of fetuses with trisomy 21 as well as in 78% of those with other chromosomal abnormalities. In 1997, Reynders et al. investigated the significance and outcome of first-trimester isolated fetal NT in 44 fetuses and found that 12% had chromosomal abnormalities, whereas in other 36 euploid NT fetuses, 1 fetus had NS, 1 fetus had Joubert syndrome, and 1 fetus had autosomal recessive polycystic kidney disease. In 1999, Adekunle et al. investigated the fetal outcome with increased NT in the first trimester. They found a prevalence of 0.8% (n = 53) of increased NT in the first trimester. They also found that in the fetuses with increased NT, 28.3% (15/53) had chromosomal abnormalities. Of the other 38 cases with euploid increased NT, 31 cases had live births, of which 2 had developmental delay, and 1 had NS. In 1999, Nisbet et al. reported six cases of NS which prenatally presented with sonographic abnormalities of increased NT, short femora, pleural effusions, hydrops, cardiac anomalies, and renal abnormalities. In 2001, Hiippala et al. investigated 50 cases with euploid increased NT and found that 8% (4/50) had major cardiac defects including 1 case with NS, 1 case with cleidocranial dysplasia, and 1 case with developmental delay. In 2009, Lee et al. reported PTPN11 analysis for the prenatal diagnosis of NS in 134 fetuses with abnormal ultrasound findings such as cystic hygroma, increased NT, and/or hydrops fetalis and found that 9% (12/134) had PTPN11 mutations. In their study, in the fetuses with cystic hygroma, 16% had PTPN11 mutations, whereas in the fetuses with increased NT, 2% had PTPN11 mutations. In 2011, Pergament et al. performed routine screening of five genes associated with NS including PTPN11, SOS1, KRAS, RAF, and MEK1 in 120 cases with euploid increased NT and found that 6.7% (8/120) had NS. In 2017, Gezdirici et al. reported two fetuses with cystic hygroma and PTPN11 mutations and suggested that PTPN11 gene testing is necessary in euploid fetuses with first-trimester cystic hygroma.
In 2017, Ali et al. performed testing for NS with the genetic testing of the genes of BRAF, HRAS, KRAS, MAP2K1, MAP2K2, NRAS, PTPN11, RAF1, RIT1, SHOC2, and SOS1 in 39 fetuses with euploid NT and found that 10.3% (4/39) had NS. In 2020, Schönfeld et al. reported rapid detection of PTPN11 mutation by hydrops panel in a fetus with NS. In 2020, Corsten-Janssen et al. reported rapid WES as a diagnostic test for multiple congenital anomalies on fetal ultrasound in 23 euploid fetuses without CMA anomalies and found that 35% (8/23) had genetic diagnosis including 1 fetus with NS and PTPN11 mutation. In 2020, Sinajon et al. applied microarray and RD testing in 226 fetuses with increased NT and found that 51.3% (116/226) had aneuploidy, and 48.7% (110/226) had normal karyotypes, of which microarray detected abnormalities in 8.2% (9/110) of the cases, and RD testing detected pathogenic variants in 2.9% (3/103) of the cases. The RD testing can detect about 80% of RDs caused by germline mutations in the RAS/MAPK pathway. RDs include NS, cardiofaciocutaneous syndrome (CFC), neurofibromatosis type 1 (NF1), NS with multiple lentigines, Costello syndrome, Legius syndrome, SYNGAP1, and central conducting lymphatic anomalies. The RD gene next-generation sequencing (NGS) panel used in the study of Sinajon et al. encompassed nine genes including BRAF, HRAS, KRAS, MAP2K1, MAP2K2, PTPN11, RAF1, SOS1, and SHOC2. In 2022, Weinstock and Sadler reported the detection of RRAS2 mutation in a fetus with severe NS and hydrocephalus. In 2022, Mellis et al. conducted a systematic review and meta-analysis to determine the diagnostic yield of WES for prenatal structural anomalies and found a diagnostic yield of 2% (95% confidence interval [CI]: 0%–5%, P = 0.04) for isolated increased NT. In 2022, Yang and Li used the 23-gene RASopathy panel (ACTB, ACTG1, BRAF, CBL, FGD1, HRAS, KAT6B, KRAS, LZTR1, MAP2K1, MAP2K2, MRAS, NF1, NRAS, PPP1CB, PTPN11, RAF1, RIT1, RRAS, SHOC2, SOS1, SOS2, and SPRED1) and WES in a fetus with increased NT and a normal array and detected an FGFR2 mutation.
In 2022, Qiu et al. detected RIT1 mutation by WES in a fetus with increased NT and NS. To date, at least 13 NS fetuses with RIT1 mutations have been identified.,,,,, Milosavljević et al. first reported detection of a de novo missense RIT1 mutation in a fetus with euploid increased NT, cystic hygroma, and hydrops fetalis and a normal CMA result by an NGS NS/RASopathy gene panel encompassing the coding sequences and splice sites of A2ML1, BRAF, CBL, HRAS, KRAS, MAP2K1, MAP2K2, NRAS, PTPN11, RAF1, RIT1, SOS1, SHOC2, and SPRED1. Yates et al. reported the application of WES on 84 deceased fetuses with ultrasound anomalies and found that 20% (17/84) were tested positive, and 9% (7/84) had only candidate gene variants including one fetus with hydrops fetalis, central nervous system malformation, congenital heart defect, NS, and RIT1 mutation. Normand et al. reported clinical WES for fetuses with ultrasound abnormalities and a suspected Mendelian disorder in 146 fetuses and yielded an overall molecular diagnostic rate of 32% (46/146) including five NS fetuses with PTPN11 (2 cases), KRAS (1 case), RIT1 (1 case), and SOS1 (1 case) mutations. Lord et al. reported prenatal WES analysis in 610 euploid fetuses with fetal structural anomalies detected by ultrasound and found that 8.5% (52/610) had diagnostic genetic variants including six NS fetuses with PTPN11 (3 cases), RIT1 (2 cases), KRAS (1 case), BRAF (1 case), and SOS1 (1 case) mutations. Petrovski et al. reported WES in the evaluation of structural anomalies in 234 euploid fetuses with structural anomalies and found that 10% (24/234) had diagnostic genetic variants including two NS fetuses with RIT1 (1 case) and SOS1 (1 case) mutations.
In summary, in this review article, a comprehensive review of NS with its prenatal diagnosis and genetic testing is presented, and the information provided is useful for ultrasonographers as well as genetic counselors.
Financial support and sponsorship
This work was supported by research grants MOST-110-2314-B-195-005 from the Ministry of Science and Technology, Taiwan, and MMH-E-111-04 from MacKay Memorial Hospital, Taipei, Taiwan.
Conflicts of interest
Prof. Chih-Ping Chen, an Editorial-in-Chief at Journal of Medical Ultrasound, had no role in the peer review process of or decision to publish this article.
|1||Tartaglia M, Mehler EL, Goldberg R, Zampino G, Brunner HG, Kremer H, et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet 2001;29:465-8.|
|2||Tartaglia M, Kalidas K, Shaw A, Song X, Musat DL, van der Burgt I, et al. PTPN11 mutations in Noonan syndrome: Molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. Am J Hum Genet 2002;70:1555-63.|
|3||Tartaglia M, Niemeyer CM, Fragale A, Song X, Buechner J, Jung A, et al. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet 2003;34:148-50.|
|4||Tartaglia M, Martinelli S, Stella L, Bocchinfuso G, Flex E, Cordeddu V, et al. Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease. Am J Hum Genet 2006;78:279-90.|
|5||Tartaglia M, Pennacchio LA, Zhao C, Yadav KK, Fodale V, Sarkozy A, et al. Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. Nat Genet 2007;39:75-9.|
|6||Tartaglia M, Zampino G, Gelb BD. Noonan syndrome: Clinical aspects and molecular pathogenesis. Mol Syndromol 2010;1:2-26.|
|7||Cowchock FS, Wapner RJ, Kurtz A, Chatzkel S, Barnhart JS Jr., Lesnick DC. Brief clinical report: Not all cystic hygromas occur in the Ullrich-Turner syndrome. Am J Med Genet 1982;12:327-31.|
|8||Nicolaides KH, Azar G, Byrne D, Mansur C, Marks K. Fetal nuchal translucency: Ultrasound screening for chromosomal defects in first trimester of pregnancy. BMJ 1992;304:867-9.|
|9||Pandya PP, Snijders RJ, Johnson SP, De Lourdes Brizot M, Nicolaides KH. Screening for fetal trisomies by maternal age and fetal nuchal translucency thickness at 10 to 14 weeks of gestation. Br J Obstet Gynaecol 1995;102:957-62.|
|10||Reynders CS, Pauker SP, Benacerraf BR. First trimester isolated fetal nuchal lucency: Significance and outcome. J Ultrasound Med 1997;16:101-5.|
|11||Adekunle O, Gopee A, el-Sayed M, Thilaganathan B. Increased first trimester nuchal translucency: Pregnancy and infant outcomes after routine screening for down's syndrome in an unselected antenatal population. Br J Radiol 1999;72:457-60.|
|12||Nisbet DL, Griffin DR, Chitty LS. Prenatal features of Noonan syndrome. Prenat Diagn 1999;19:642-7.|
|13||Hiippala A, Eronen M, Taipale P, Salonen R, Hiilesmaa V. Fetal nuchal translucency and normal chromosomes: A long-term follow-up study. Ultrasound Obstet Gynecol 2001;18:18-22.|
|14||Lee KA, Williams B, Roza K, Ferguson H, David K, Eddleman K, et al. PTPN11 analysis for the prenatal diagnosis of Noonan syndrome in fetuses with abnormal ultrasound findings. Clin Genet 2009;75:190-4.|
|15||Pergament E, Alamillo C, Sak K, Fiddler M. Genetic assessment following increased nuchal translucency and normal karyotype. Prenat Diagn 2011;31:307-10.|
|16||Gezdirici A, Ekiz A, Güleç EY, Kaya B, Sezer S, Atış Aydın A. How necessary is to analyze PTPN11 gene in fetuses with first trimester cystic hygroma and normal karyotype? J Matern Fetal Neonatal Med 2017;30:938-41.|
|17||Ali MM, Chasen ST, Norton ME. Testing for Noonan syndrome after increased nuchal translucency. Prenat Diagn 2017;37:750-3.|
|18||Schönfeld M, Selig M, Russo A, Lindner C, Kampmann C, Mildenberger E, et al. Rapid detection by hydrops panel of Noonan syndrome with PTPN11 mutation (p.Thr73Ile) and persistent thrombocytopenia. Mol Genet Genomic Med 2020;8:e1174.|
|19||Corsten-Janssen N, Bouman K, Diphoorn JC, Scheper AJ, Kinds R, El Mecky J, et al. A prospective study on rapid exome sequencing as a diagnostic test for multiple congenital anomalies on fetal ultrasound. Prenat Diagn 2020;40:1300-9.|
|20||Sinajon P, Chitayat D, Roifman M, Wasim S, Carmona S, Ryan G, et al. Microarray and RASopathy-disorder testing in fetuses with increased nuchal translucency. Ultrasound Obstet Gynecol 2020;55:383-90.|
|21||Rauen KA. Defining RASopathy. Dis Model Mech 2022;15:dmm049344.|
|22||Weinstock NI, Sadler L. The RRAS2 pathogenic variant p.Q72L produces severe Noonan syndrome with hydrocephalus: A case report. Am J Med Genet A 2022;188:364-8.|
|23||Mellis R, Oprych K, Scotchman E, Hill M, Chitty LS. Diagnostic yield of exome sequencing for prenatal diagnosis of fetal structural anomalies: A systematic review and meta-analysis. Prenat Diagn 2022;42:662-85.|
|24||Yang YD, Li DZ. Further genetic testing in fetuses with increased nuchal translucency and a normal array: A targeted panel or exome? Taiwan J Obstet Gynecol 2022;61:562-3.|
|25||Qiu Z, Chang WT, Chou YC, Wen KC, Ziying Y, Yuen K, et al. Prenatal case of RIT1 mutation associated Noonan syndrome by whole exome sequencing (WES) and review of the literature. Taiwan J Obstet Gynecol 2022;61:535-8.|
|26||Milosavljević D, Overwater E, Tamminga S, de Boer K, Elting MW, van Hoorn ME, et al. Two cases of RIT1 associated Noonan syndrome: Further delineation of the clinical phenotype and review of the literature. Am J Med Genet 2016;170A: 1874-80.|
|27||Yates CL, Monaghan KG, Copenheaver D, Retterer K, Scuffins J, Kucera CR, et al. Whole-exome sequencing on deceased fetuses with ultrasound anomalies: Expanding our knowledge of genetic disease during fetal development. Genet Med 2017;19:1171-8.|
|28||Normand EA, Braxton A, Nassef S, Ward PA, Vetrini F, He W, et al. Clinical exome sequencing for fetuses with ultrasound abnormalities and a suspected Mendelian disorder. Genome Med 2018;10:74.|
|29||Lord J, McMullan DJ, Eberhardt RY, Rinck G, Hamilton SJ, Quinlan-Jones E, et al. Prenatal exome sequencing analysis in fetal structural anomalies detected by ultrasonography (PAGE): A cohort study. Lancet 2019;393:747-57.|
|30||Petrovski S, Aggarwal V, Giordano JL, Stosic M, Wou K, Bier L, et al. Whole-exome sequencing in the evaluation of fetal structural anomalies: A prospective cohort study. Lancet 2019;393:758-67.|